Introduction: Tuberculosis continues to be a major cause of morbidity and mortality
worldwide. Currently available drugs are effective for treatment of the disease or latent …

Abstract The American Thoracic Society, Centers for Disease Control and Prevention, and
Infectious Diseases Society of America jointly sponsored the development of this guideline …

This report updates and combines earlier versions of guidelines for the prevention and
treatment of opportunistic infections (OIs) in HIV-infected adults (ie, persons aged> 18 years) …

The incidence of drug-induced thrombocytopenia (DIT) is not well-defined, but is estimated
to occur at a minimum of 10 cases per million per year. This review will focus on the potential …

BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and
treatment interruption. The aim of these clinical standards is to encourage best practise for …

Diagnosing and treating latent tuberculosis infection (LTBI) is an important part of efforts to
combat tuberculosis (TB). The Korean guidelines for TB published in 2020 recommend 2 …

Thrombocytopenia is a major adverse effect of several drug treatments. Rifampicin has been
recognized as a cause of immune thrombocytopenia during intermittent high‐dose therapy …

The management of tuberculosis (TB) can be a challenging process that has implications
both for the affected patient and public health. Effective anti-TB chemotherapy both cures …

The drug-dependent antibody of a patient with rifampicin-induced thrombocytopenia was
characterized using the antigen-capture enzyme-linked immunosorbent assay (MAIPA …

Immune thrombocytopenia is a common complication of therapy with a large number of
drugs. The most widely studied drug-induced immune thrombocytopenia (DIT) is caused by …